95 related articles for article (PubMed ID: 15159018)
1. The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice.
Suckow MA; Gutierrez LS; Risatti CA; Wolter WR; Taylor RE; Pollard M; Navari RM; Castellino FJ; Paoni NF
Cancer Lett; 2004 Jun; 209(2):165-9. PubMed ID: 15159018
[TBL] [Abstract][Full Text] [Related]
2. Ephrin-A1 promotes the malignant progression of intestinal tumors in Apc(min/+) mice.
Shi L; Itoh F; Itoh S; Takahashi S; Yamamoto M; Kato M
Oncogene; 2008 May; 27(23):3265-73. PubMed ID: 18246128
[TBL] [Abstract][Full Text] [Related]
3. The threshold level of adenomatous polyposis coli protein for mouse intestinal tumorigenesis.
Li Q; Ishikawa TO; Oshima M; Taketo MM
Cancer Res; 2005 Oct; 65(19):8622-7. PubMed ID: 16204028
[TBL] [Abstract][Full Text] [Related]
4. Phospholipase Cepsilon promotes intestinal tumorigenesis of Apc(Min/+) mice through augmentation of inflammation and angiogenesis.
Li M; Edamatsu H; Kitazawa R; Kitazawa S; Kataoka T
Carcinogenesis; 2009 Aug; 30(8):1424-32. PubMed ID: 19458037
[TBL] [Abstract][Full Text] [Related]
5. Liposome-mediated adenomatous polyposis coli gene therapy: a novel anti-adenoma strategy in multiple intestinal neoplasia mouse model.
Lee J; Hargest R; Wasan H; Phillips RK
Dis Colon Rectum; 2004 Dec; 47(12):2105-13. PubMed ID: 15657662
[TBL] [Abstract][Full Text] [Related]
6. Impact of genetic background on spontaneous or 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced intestinal tumorigenesis in Min/+ mice.
Steffensen IL; Alexander J
Cancer Lett; 2006 Aug; 240(2):289-96. PubMed ID: 16343741
[TBL] [Abstract][Full Text] [Related]
7. Myh deficiency enhances intestinal tumorigenesis in multiple intestinal neoplasia (ApcMin/+) mice.
Sieber OM; Howarth KM; Thirlwell C; Rowan A; Mandir N; Goodlad RA; Gilkar A; Spencer-Dene B; Stamp G; Johnson V; Silver A; Yang H; Miller JH; Ilyas M; Tomlinson IP
Cancer Res; 2004 Dec; 64(24):8876-81. PubMed ID: 15604247
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutational mechanisms involved in intestinal tumor formation in Min mice.
Shoemaker AR; Luongo C; Moser AR; Marton LJ; Dove WF
Cancer Res; 1997 May; 57(10):1999-2006. PubMed ID: 9157997
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of intestinal polyposis with reduced angiogenesis in ApcMin/+ mice due to decreases in c-Myc expression.
Yekkala K; Baudino TA
Mol Cancer Res; 2007 Dec; 5(12):1296-303. PubMed ID: 18171987
[TBL] [Abstract][Full Text] [Related]
10. Role of nucleotide excision repair deficiency in intestinal tumorigenesis in multiple intestinal neoplasia (Min) mice.
Steffensen IL; Schut HA; Nesland JM; Tanaka K; Alexander J
Mutat Res; 2006 Dec; 611(1-2):71-82. PubMed ID: 16962818
[TBL] [Abstract][Full Text] [Related]
11. Growth stimulation of intestinal tumours in Apc(Min/+) mice by dietary L-methionine supplementation.
Paulsen JE; Alexander J
Anticancer Res; 2001; 21(5):3281-4. PubMed ID: 11848484
[TBL] [Abstract][Full Text] [Related]
12. X radiation up-regulates the occurrence and the multiplicity of invasive carcinomas in the intestinal tract of Apc(min/+) mice.
Nakayama T; Yamazumi K; Uemura T; Yoshizaki A; Yakata Y; Matsuu-Matsuyama M; Shichijo K; Sekine I
Radiat Res; 2007 Oct; 168(4):433-9. PubMed ID: 17903035
[TBL] [Abstract][Full Text] [Related]
13. Compound disruption of smad2 accelerates malignant progression of intestinal tumors in apc knockout mice.
Hamamoto T; Beppu H; Okada H; Kawabata M; Kitamura T; Miyazono K; Kato M
Cancer Res; 2002 Oct; 62(20):5955-61. PubMed ID: 12384562
[TBL] [Abstract][Full Text] [Related]
14. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis.
Zeilstra J; Joosten SP; Dokter M; Verwiel E; Spaargaren M; Pals ST
Cancer Res; 2008 May; 68(10):3655-61. PubMed ID: 18483247
[TBL] [Abstract][Full Text] [Related]
15. Apc mice: models, modifiers and mutants.
McCart AE; Vickaryous NK; Silver A
Pathol Res Pract; 2008; 204(7):479-90. PubMed ID: 18538487
[TBL] [Abstract][Full Text] [Related]
16. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice.
Yue HH; Diehl GE; Winoto A
Cell Death Differ; 2005 Jan; 12(1):94-7. PubMed ID: 15514675
[No Abstract] [Full Text] [Related]
17. Ranolazine. A metabolic modulator for the treatment of chronic stable angina.
Anderson JR; Nawarskas JJ
Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056
[TBL] [Abstract][Full Text] [Related]
18. Adiponectin suppresses tumorigenesis in Apc(Min)(/+) mice.
Otani K; Kitayama J; Yasuda K; Nio Y; Iwabu M; Okudaira S; Aoki J; Yamauchi T; Kadowaki T; Nagawa H
Cancer Lett; 2010 Feb; 288(2):177-82. PubMed ID: 19646806
[TBL] [Abstract][Full Text] [Related]
19. beta-Catenin-accumulated crypts in the colonic mucosa of juvenile ApcMin/+ mice.
Hata K; Tanaka T; Kohno H; Suzuki R; Qiang SH; Yamada Y; Oyama T; Kuno T; Hirose Y; Hara A; Mori H
Cancer Lett; 2006 Jul; 239(1):123-8. PubMed ID: 16168560
[TBL] [Abstract][Full Text] [Related]
20. Genetic background affects susceptibility to mammary hyperplasias and carcinomas in Apc(min)/+ mice.
Moser AR; Hegge LF; Cardiff RD
Cancer Res; 2001 Apr; 61(8):3480-5. PubMed ID: 11309311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
